Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

Who May Qualify: 1. Diagnosed as recurrent hepatocellular carcinoma after curative treatment; 2. The criteria for resectability is met; 3. Has at least one evaluable lesion according to the RECIST 1.1 standard and has not received local treatment; 4. Eastern Cooperative Oncology Group score 0-1, Child-pugh score 5-7; 5. Agree to biopsy and blood sample collection; 6. Adequate organ and marrow function. Who Should NOT Join This Trial: 1. Previously received any transarterial chemoembolization and immune therapy and other local or systemic liver cancer treatments, except for curative ablation; 2. Extrahepatic metastasis; 3. History of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding; 4. History of autoimmune conditions (where your immune system attacks your own body) or need to take immunosuppressant drugs for a long time; 5. History of testing positive for human weakened immune system virus (HIV) or known acquired weakened immune system syndrome (AIDS); 6. Abnormal organ function Always talk to your doctor about whether this trial is right for you.